Cerevel Therapeutics ticks higher amid Nasdaq delisting notice for AbbVie deal
by
Contributor since / Followers
Contributor since / Followers
5 months ago
vzphotos/iStock Editorial via Getty Images
- Cerevel Therapeutics (NASDAQ:CERE) edged higher by 0.5% in premarket trading after a Nasdaq delisting notice for its planned sale to AbbVie (NYSE:ABBV).
- The deal is tentatively scheduled to close prior to the market open on Thursday and the stock will be halted immediately follow the after-hours session on Wednesday, according to the Nasdaq notice posted on Wednesday.
- AbbVie (ABBV) CEO Rob Michael said last Thursday that the Cerevel (CERE) deal will close soon, possibly as soon as this week.